Home » Stocks » NK

NantKwest, Inc. (NK)

Stock Price: $32.51 USD -1.67 (-4.89%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $31.66 -0.85 (-2.62%) Feb 26, 7:59 PM
Market Cap 3.54B
Revenue (ttm) 99,000
Net Income (ttm) -75.89M
Shares Out 108.25M
EPS (ttm) -0.75
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $32.51
Previous Close $34.18
Change ($) -1.67
Change (%) -4.89%
Day's Open 33.95
Day's Range 30.80 - 35.91
Day's Volume 1,405,933
52-Week Range 2.52 - 45.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 2 weeks ago

The FDA has signed off the expansion of Phase 1 testing of a COVID-19 vaccine candidate, developed by NantKwest Inc's (NASDAQ: NK) merger partner, ImmunityBio Inc, to include sublingual boosts...

Business Wire - 2 weeks ago

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics comp...

Business Wire - 3 weeks ago

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of NantKw...

PRNewsWire - 1 month ago

BERWYN, Pa., Jan. 21, 2021 /PRNewswire/ -- RM LAW, P.C. is investigating potential claims against the board of directors of NantKwest, Inc. ("NantKwest" or the "Company") (NASDAQ: NK) concerni...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a nationally ranked and award-winning shareholder rights law firm, is investigating potential securities violations and breach of fiduciary duty ag...

GlobeNewsWire - 1 month ago

PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company's shareholders.

Business Wire - 1 month ago

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurod...

Seeking Alpha - 1 month ago

NantKwest and ImmunityBio announced they are preparing to merge to create a juggernaut immunotherapy and cell therapy company. Now, NantKwest investors will have ownership of ImmunityBio's imp...

Benzinga - 1 month ago

Clinical-stage immunotherapy company Nantkwest Inc (NASDAQ: NK) reports positive interim data on survival rates in the Metastatic Pancreatic Cancer QUILT 88 trial on Wednesday. What Happened: ...

Business Wire - 1 month ago

EL SEGUNDO & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, Inc., a privately-held immun...

Business Wire - 1 month ago

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Dr. Patrick Soon-Shiong M.D., Executiv...

The Motley Fool - 1 month ago

"Natural killer" (or NK) cancer therapies are hot right now. Here are two stocks that are early leaders in the field -- one is a buy, and the other one is not.

GlobeNewsWire - 1 month ago

PHILADELPHIA, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ: NK) on behalf of the company's shareholders.

GlobeNewsWire - 1 month ago

WILMINGTON, Del., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potent...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of NantKwest, Inc. (NASDAQ:NK) and ImmunityBio is fair to NantKwest sharehol...

PRNewsWire - 2 months ago

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

GlobeNewsWire - 2 months ago

WILMINGTON, Del., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating NantKwest, Inc. (“NantKwest”) (NASDAQ GS: NK) regarding possible breaches of fiduc...

CNBC Television - 2 months ago

NantKwest's Patrick Soon-Shiong on reverse merger with ImmunityBio

NantKwest announces a reverse merger with a frequent collaborator ImmunityBio in a stock-for-stock deal. Patrick Soon-Shiong, NantKwest executive chairman and NantWorks chairman and CEO, joins...

Zacks Investment Research - 2 months ago

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: CRSP, DNLI, MCRB, RCKT
Business Wire - 2 months ago

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neuro...

PRNewsWire - 2 months ago

NEW YORK, Dec. 21, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of NantKwest, Inc. ("NantKwest" ...

The Motley Fool - 2 months ago

A merger agreement with a fellow immunotherapy company is exciting investors today.

Business Wire - 2 months ago

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based th...

Business Wire - 3 months ago

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced its participation in the virtual 32nd Annua...

Business Wire - 3 months ago

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based th...

Business Wire - 4 months ago

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today appointed healthcare industry veteran with proven ope...

Seeking Alpha - 4 months ago

NantKwest announces initiation of second generation COVID-19 vaccine candidate. Protagonist Therapeutics receives orphan drug status for PTG-300.

Business Wire - 4 months ago

CULVER CITY, Calif. & EL SEGUNDO, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based th...

Business Wire - 4 months ago

EL SEGUNDO, Calif. & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held imm...

Business Wire - 5 months ago

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman an...

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--Brink Biologics, Inc. (“Brink”), a NantKwest, Inc.

Business Wire - 6 months ago

EL SEGUNDO, Calif. & CULVER CITY, Calif.

PRNewsWire - 6 months ago

LOS ANGELES, and EL SEGUNDO, Calif., Aug. 10, 2020 /PRNewswire/ -- CBR® by Generate Life Sciences, the world's largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-st...

Zacks Investment Research - 6 months ago

NantKwest (NK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 7 months ago

My COVID-19 Vaccine Report Card

Other stocks mentioned: ALT, DVAX, NVAX, VBIV
Seeking Alpha - 7 months ago

NantKwest: The Market And The Government Are Missing Out On This Blockbuster

Business Wire - 7 months ago

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced und...

Business Wire - 8 months ago

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the pricing of an underwritten public offer...

Business Wire - 8 months ago

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that it intends to offer and sell, subject ...

The Motley Fool - 8 months ago

Investors are excited about the biotech's COVID-19 vaccine targeting a different part of the novel coronavirus.

Benzinga - 9 months ago

Nantkwest Inc (NASDAQ: NK) shares spiked after the company announced progress on the COVID-19 vaccine program and therapeutics options.

Benzinga - 10 months ago

Shares of small-cap immunotherapy company Nantkwest Inc (NASDAQ: NK), a leading producer of clinical dose forms of off-the-shelf natural killer cell therapies, were adding to Monday's gains in...

Zacks Investment Research - 1 year ago

Investors need to pay close attention to NantKwest (NK) stock based on the movements in the options market lately.

The Motley Fool - 1 year ago

Shares soar after the clinical-stage biotech releases exciting news.

Seeking Alpha - 1 year ago

NantKwest: The Market Finally Recognizes The Opportunity

Seeking Alpha - 1 year ago

NantKwest has recently reported positive results and progress in its NK cell pipeline programs, but the shares have continued to sell off.

Seeking Alpha - 1 year ago

NantKwest was a highly anticipated IPO that only took a couple of years to be "busted" Although the stock might be busted, the company is still making headway.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in NantKwest.

About NK

NantKwest, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cance... [Read more...]

Industry
Biotechnology
IPO Date
Jul 28, 2015
CEO
Patrick Soon-Shiong
Employees
160
Stock Exchange
NASDAQ
Ticker Symbol
NK
Full Company Profile

Financial Performance

In 2019, NantKwest's revenue was $43,000, a decrease of -8.51% compared to the previous year's $47,000. Losses were -$65.79 million, -31.63% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for NantKwest stock is "Buy" and the 12-month stock price forecast is 18.00.

Price Target
$18.00
Analyst Consensus: Buy